Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
COVID-19 is associated with a cytokine storm that leads to respiratory distress, multiorgan failure and elevated mortality. Oral Colchicine exhibits high anti-inflammatory capacity attributed to the inhibition of microtubules polymerization, inflammasome and production of IL-1β and IL-6, which could prevent the inflammatory storm in COVID-19 patients at risk. The investigators present a randomized, controlled, open-labeled, and pragmatic clinical trial to study the treatment effect of Colchicine in COVID-19 patients requiring hospitalization, but no intensive care yet. Colchicine will be started within the first 48 hours and continue for 14 days using a descending dose. The benefits will be studied in terms of clinical evolution (WHO 7-point scale) and IL-6 levels, as well as other clinical and biochemical secondary end-points. In the case of positive results, the clinical impact would be relevant given that this oral medication is affordable and widely accessible which would help to prevent the inflammatory complications associated with COVID-19.
Description: Improvement in the clinical evolution of patients
Measure: Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group Time: up to 14 daysDescription: Improvement in cytokine level
Measure: Changes in IL-6 concentrations Time: up to 14 daysDescription: time needed to reduce at least 2 points in the 7-point Ordinal Scale for Clinical Improvement by WHO R&D Blueprint expert group (0-7)
Measure: Improvement in the clinical status Time: up to 14 daysDescription: Sequential Organ Failure Assessment (SOFA score) (0-14)
Measure: Changes in the score for the Sequential Organ Failure Assessment (SOFA score) Time: up to 14 daysDescription: National Early Warning Score (NEWS scale)
Measure: Changes in the punctuation in the National Early Warning Score Time: up to 14 daysDescription: C-reactive protein
Measure: Changes in other inflammatory markers Time: up to 14 daysDescription: D-dimer
Measure: Changes in severity markers Time: up to 14 daysDescription: Leukocytes
Measure: Changes in severity markers Time: up to 14 daysDescription: Lymphocytes
Measure: Changes in severity markers Time: up to 14 daysDescription: Platelets
Measure: Changes in severity markers Time: up to 14 daysDescription: LDH
Measure: Changes in severity markers Time: up to 14 daysDescription: Ferritin
Measure: Changes in severity markers Time: up to 14 daysDescription: myocardial stress markers hsTnT
Measure: Changes in myocardial damage Time: up to 14 daysDescription: myocardial stress markers NT-proBNP
Measure: Changes in myocardial damage Time: up to 14 daysDescription: RT-PCR assay
Measure: Time until reaching a virus negative status Time: up to 14 daysDescription: Length of hospital stay
Measure: Length of hospital stay Time: up to 14 daysDescription: Number of days in the intensive care unit.
Measure: Number of days in the intensive care unit. Time: up to 14 daysDescription: Mortality
Measure: Mortality Time: up to 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports